Dianthus Therapeutics Inc.

Stock Chart, Company Information, and Scan Results

$21.09(as of Jul 9, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Dianthus Therapeutics Inc. Company Information, Fundamentals, and Technical Indicators

Stock Price$21.09
Ticker SymbolDNTH
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees78
CountyUSA
Market Cap$586.9M
EBIDTA-117.1M
10-Day Moving Average18.55
P/E Ratio-7.49
20-Day Moving Average18.26
Forward P/E Ratio0.00
50-Day Moving Average18.90
Earnings per Share-2.83
200-Day Moving Average22.31
Profit Margin-2,537.49%
RSI65.16
Shares Outstanding32.16M
ATR1.41
52-Week High32.27
Volume1,367,316
52-Week Low13.37
Most Recent Support Level17.88
Book Value328.6M
Most Recent Resistance Level19.46
P/B Ratio2.30
Upper Keltner21.42
P/S Ratio115.70
Lower Keltner15.09
Debt-to-Equity Ratio21.42
Next Earnings DateUnknown
Cash Surplus-6.8M
Next Ex-Dividend DateUnknown

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.